AASK COHORT STUDY

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。非裔美国人肾脏疾病和高血压研究(AASK)队列研究是一项前瞻性的观察性研究，将是AASK临床试验的发展。AASK试验是一项随机试验，测试了作为一线降压治疗的3种不同药物(雷米普利、美托洛尔和氨氯地平)和2种血压控制水平(通常控制和更积极控制)对肾功能(肾小球滤过率和临床肾脏事件)的影响。在4-6年前被随机纳入AASK试验的1094名参与者中，我们预计650-750名尚未达到终末期肾病(ESRD)的患者将参加AASK队列研究。此外，那些在AASK试验期间到达ESRD的人将被要求参加一次访问以收集脱氧核糖核酸(DNA)。AASK队列参与者每年将有2次数据收集访问和最多4次额外的血压管理访问。要监测的暴露包括环境、遗传、生理和社会经济因素。主要的肾脏结果将是一个临床结果，其定义是血肌酐增加一倍，达到终末期肾病，或死亡。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The African American Study of Kidney Disease and Hypertension (AASK) Cohort Study is a prospective, observational study that will be a development from the AASK clinical trial. The AASK trial was a randomized trial that tested the effect on kidney function (glomerular filtration rate and clinical kidney events) of 3 different medications used as first line antihypertensive therapy (ramipril, metoprolol and amlodipine) and 2 levels of blood pressure control (usual control and more aggressive control). Of the 1,094 participants randomized into the AASK trial 4-6 years ago, we anticipate that 650-750 individuals who have not reached end-stage renal disease (ESRD) will enroll in the AASK Cohort study. In addition, those individuals who reached ESRD during the AASK trial will be asked to participate for one visit for collection of deoxyribonucleic acid (DNA). The AASK Cohort participants will have 2 data collection visits each year and up to 4 additional visits for blood pressure management. Exposures to be monitored include environmental, genetic, physiologic, and socio-economic factors. The primary renal outcome will be a clinical outcome defined by doubling of serum creatinine, attainment of ESRD, or death.